LeMaitre Vascular, Inc. (NASDAQ:LMAT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July1, 2017, Michael T. Wijas, who served as Vice President, Sales, The Americas, of LeMaitre Vascular, Inc. (the “Company”), notified the Company of his resignation from the Company, effective July7, 2017.

The Company has initiated a search for a replacement. In the interim, the North American sales management team will report to George W. LeMaitre, Chairman and Chief Executive Officer of the Company.

Item 5.02 Regulation FD Disclosure.

The Company expects preliminary unaudited second quarter 2017 sales to be in the range of $25.4 million to $25.7 million.

As the Company’s Q2 2017 sales information presented in this report is preliminary and unaudited, it remains subject to adjustment. This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this report regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected. Risks and uncertainties that may affect the Company’s future results include, but are not limited to, those discussed under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov.

The information contained in this Item 5.02 is being furnished and shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing.

About LeMaitre Vascular, Inc. (NASDAQ:LMAT)

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.